论文部分内容阅读
目的探讨吉西他滨联合长春瑞宾治疗复治晚期非小细胞肺癌的疗效及安全性。方法 20例复治的Ⅳ期非小细胞肺癌患者接受吉西他滨联合长春瑞宾的化疗,方案:吉西他滨1g/m2,静脉推注,第1、8天,长春瑞宾25mg/m2,第1、8天,静脉推注,每3周一次。结果 20例患者中PR4例,SD9例,PD7例,有效率(CR+PR)为20%。主要的化疗反应为骨髓抑制、胃肠道反应,所有患者均能耐受。结论吉西他滨联合长春瑞宾治疗复治晚期非小细胞肺癌有效,不良反应较小,患者更容易耐受。
Objective To investigate the efficacy and safety of gemcitabine and vinorelbine in the treatment of advanced non-small cell lung cancer. Methods Twenty patients with re-treatment of stage Ⅳ non-small cell lung cancer underwent gemcitabine plus vinorelbine chemotherapy. The regimen included gemcitabine 1 g / m 2, intravenous bolus, day 1,8, vinorelbine 25 mg / m 2, Day, intravenous injection, once every 3 weeks. Results Among the 20 patients, 4 were PR4, SD9 and PD7, and the effective rate (CR + PR) was 20%. The main chemotherapy response for bone marrow suppression, gastrointestinal reactions, all patients can tolerate. Conclusion Gemcitabine combined with vinorelbine is effective in the treatment of advanced non-small cell lung cancer (NSCLC), with less adverse reactions and more tolerable patients.